Pharmacogenetics and nutritional supplementation in age-related macular degeneration

Blake M. Hampton, Jaclyn Kovach, Stephen Schwartz

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The Age-Related Eye Disease Study (AREDS) recommended treatment with antioxidants plus zinc in patients with intermediate or advanced age-related macular degeneration in order to reduce progression risks. Recent pharmacogenetic studies have reported differences in treatment outcomes with respect to variants in genes for CFH and ARMS2, although the treatment recommendations based on these differences are controversial. Different retrospective analyses of subsets of patients from the same AREDS trial have drawn different conclusions. The practicing clinician, who is not an expert on genetics, clinical trial design, or statistical analysis, may be uncertain how to interpret these results. Based on the balance of the available literature, we suggest not changing established practice recommendations until additional evidence from clinical trials becomes available.

Original languageEnglish (US)
Pages (from-to)873-876
Number of pages4
JournalClinical Ophthalmology
Volume9
DOIs
StatePublished - May 15 2015

Fingerprint

Eye Diseases
Pharmacogenetics
Macular Degeneration
Clinical Trials
Zinc
Antioxidants
Therapeutics
Genes
Pharmacogenomic Testing

Keywords

  • Age-Related Eye Disease Study (AREDS)
  • Age-related macular degeneration
  • Age-related maculopathy susceptibility 2 (ARMS2)
  • Complement factor H (CFH)
  • Pharmacogenetics
  • Randomized clinical trial (RCT)

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Pharmacogenetics and nutritional supplementation in age-related macular degeneration. / Hampton, Blake M.; Kovach, Jaclyn; Schwartz, Stephen.

In: Clinical Ophthalmology, Vol. 9, 15.05.2015, p. 873-876.

Research output: Contribution to journalArticle

@article{915ef9e2e4204cf6bc51cc4bca0a4d8f,
title = "Pharmacogenetics and nutritional supplementation in age-related macular degeneration",
abstract = "The Age-Related Eye Disease Study (AREDS) recommended treatment with antioxidants plus zinc in patients with intermediate or advanced age-related macular degeneration in order to reduce progression risks. Recent pharmacogenetic studies have reported differences in treatment outcomes with respect to variants in genes for CFH and ARMS2, although the treatment recommendations based on these differences are controversial. Different retrospective analyses of subsets of patients from the same AREDS trial have drawn different conclusions. The practicing clinician, who is not an expert on genetics, clinical trial design, or statistical analysis, may be uncertain how to interpret these results. Based on the balance of the available literature, we suggest not changing established practice recommendations until additional evidence from clinical trials becomes available.",
keywords = "Age-Related Eye Disease Study (AREDS), Age-related macular degeneration, Age-related maculopathy susceptibility 2 (ARMS2), Complement factor H (CFH), Pharmacogenetics, Randomized clinical trial (RCT)",
author = "Hampton, {Blake M.} and Jaclyn Kovach and Stephen Schwartz",
year = "2015",
month = "5",
day = "15",
doi = "10.2147/OPTH.S84155",
language = "English (US)",
volume = "9",
pages = "873--876",
journal = "Clinical Ophthalmology",
issn = "1177-5467",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Pharmacogenetics and nutritional supplementation in age-related macular degeneration

AU - Hampton, Blake M.

AU - Kovach, Jaclyn

AU - Schwartz, Stephen

PY - 2015/5/15

Y1 - 2015/5/15

N2 - The Age-Related Eye Disease Study (AREDS) recommended treatment with antioxidants plus zinc in patients with intermediate or advanced age-related macular degeneration in order to reduce progression risks. Recent pharmacogenetic studies have reported differences in treatment outcomes with respect to variants in genes for CFH and ARMS2, although the treatment recommendations based on these differences are controversial. Different retrospective analyses of subsets of patients from the same AREDS trial have drawn different conclusions. The practicing clinician, who is not an expert on genetics, clinical trial design, or statistical analysis, may be uncertain how to interpret these results. Based on the balance of the available literature, we suggest not changing established practice recommendations until additional evidence from clinical trials becomes available.

AB - The Age-Related Eye Disease Study (AREDS) recommended treatment with antioxidants plus zinc in patients with intermediate or advanced age-related macular degeneration in order to reduce progression risks. Recent pharmacogenetic studies have reported differences in treatment outcomes with respect to variants in genes for CFH and ARMS2, although the treatment recommendations based on these differences are controversial. Different retrospective analyses of subsets of patients from the same AREDS trial have drawn different conclusions. The practicing clinician, who is not an expert on genetics, clinical trial design, or statistical analysis, may be uncertain how to interpret these results. Based on the balance of the available literature, we suggest not changing established practice recommendations until additional evidence from clinical trials becomes available.

KW - Age-Related Eye Disease Study (AREDS)

KW - Age-related macular degeneration

KW - Age-related maculopathy susceptibility 2 (ARMS2)

KW - Complement factor H (CFH)

KW - Pharmacogenetics

KW - Randomized clinical trial (RCT)

UR - http://www.scopus.com/inward/record.url?scp=84929577020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929577020&partnerID=8YFLogxK

U2 - 10.2147/OPTH.S84155

DO - 10.2147/OPTH.S84155

M3 - Article

AN - SCOPUS:84929577020

VL - 9

SP - 873

EP - 876

JO - Clinical Ophthalmology

JF - Clinical Ophthalmology

SN - 1177-5467

ER -